Regulatory Submissions and Approval Processes

Regulatory submissions are the structured dossiers through which a manufacturer presents the quality, safety, and efficacy evidence for a medicine so that a health authority can decide whether to authorise it. Approval processes are the regulatory procedures, with their defined formats, review timelines, and decision standards, by which those submissions are evaluated and a product is permitted onto the market.

Definition

A regulatory submission is a documented application presenting the quality, non-clinical, and clinical evidence for a medicinal product to a health authority, and the approval process is the procedure by which that authority reviews the evidence and decides whether to grant a marketing authorisation.

Scope

This entry covers the purpose and structure of regulatory submissions, the harmonised Common Technical Document format, the principal application types and pathways, and the review and decision steps that lead to marketing authorisation and post-approval maintenance. It is a reference and educational overview of how medicines are approved, and does not advise on any specific application or jurisdiction.

Core questions

• What evidence must a submission contain to support authorisation of a medicine?
• How is that evidence organised so that authorities across regions can review it?
• What application types and pathways exist for new, generic, and special-case products?
• How are products maintained and varied after approval?

Key concepts

• Common Technical Document (CTD/eCTD)
• Quality, safety, and efficacy modules
• New drug and biologics applications
• Abbreviated and generic pathways
• Marketing authorisation
• Expedited and conditional pathways
• Post-approval variations and lifecycle maintenance
• Regulatory review and decision

Mechanisms

A submission assembles the evidence for a medicine into a defined structure, internationally harmonised as the Common Technical Document with modules covering administrative information and quality, non-clinical, and clinical data. A health authority then reviews the dossier against legal standards of quality, safety, and efficacy, may seek clarification or inspect facilities, and reaches a decision to authorise, refuse, or request further data. After approval, the authorisation is maintained through controlled variations and periodic reporting, so the regulatory record continues to reflect the product as manufactured.

Clinical relevance

The approval process is what determines whether and on what terms a medicine becomes available to clinicians and patients, and the resulting label defines its authorised indications and conditions of use. This entry describes how medicines are evaluated and authorised and is not itself a source of prescribing or treatment guidance.

Evidence & guidelines

Submission structure is harmonised internationally through the ICH M4 Common Technical Document, while application types and procedures are defined by national and regional authorities such as the FDA (for new drug and biologics applications) and the EMA (for centralised and other marketing-authorisation procedures). Analyses such as that by Darrow and colleagues describe how approval standards and expedited pathways have evolved over recent decades.

History

Pre-market approval of medicines was established in the mid-twentieth century after safety crises led legislatures to require evidence of safety and, later, efficacy before marketing. Submission requirements initially differed sharply between countries, but from the 1990s the International Council for Harmonisation aligned technical content and introduced the Common Technical Document, while electronic submission (eCTD) and expedited pathways for serious conditions reshaped review in the following decades.

Debates

How should speed of access be balanced against certainty of evidence?

Expedited and conditional approval pathways can bring needed medicines to patients sooner but may rely on surrogate endpoints or less mature data, raising ongoing debate about the appropriate evidentiary standard at the time of approval.

Seminal works

• ich-m4-2016

Frequently asked questions

What is the Common Technical Document?

It is an internationally harmonised format that organises a submission into modules for administrative information and for quality, non-clinical, and clinical data, so that the same dossier structure can be reviewed by authorities in different regions.

Does approval in one country mean a medicine is approved everywhere?

No; marketing authorisation is granted by each authority or region under its own procedures, though harmonised submission formats and shared evidence make multi-region applications more efficient.